Bouquin et al. - High variability in the reproducibility of key hemodynamic responses to head-up tilt by Heidi Bouquin (17563521)

“…Median time gap between the first and the second HUT was 9 weeks and the second and the third HUT 4 weeks. We utilized whole-body impedance cardiography and radial artery tonometry as methods. …”

Image4_Constructing more comprehensive pollination networks: integrating diurnal and nocturnal pollen data with visitation in a subalpine wetland community.jpeg by Yue Teng (621662)

“…</p>Results<p>We observed 41 plant and 154 pollinator species, corresponding to 665 specific interactions. …”

Image1_Constructing more comprehensive pollination networks: integrating diurnal and nocturnal pollen data with visitation in a subalpine wetland community.jpeg by Yue Teng (621662)

“…</p>Results<p>We observed 41 plant and 154 pollinator species, corresponding to 665 specific interactions. …”

Table2_Constructing more comprehensive pollination networks: integrating diurnal and nocturnal pollen data with visitation in a subalpine wetland community.docx by Yue Teng (621662)

“…</p>Results<p>We observed 41 plant and 154 pollinator species, corresponding to 665 specific interactions. …”

Bouquin et al. - High variability in the reproducibility of key hemodynamic responses to head-up tilt by Heidi Bouquin (17563521)

“…Median time gap between the first and the second HUT was 9 weeks and the second and the third HUT 4 weeks. We utilized whole-body impedance cardiography and radial artery tonometry as methods. …”

Image3_Constructing more comprehensive pollination networks: integrating diurnal and nocturnal pollen data with visitation in a subalpine wetland community.jpeg by Yue Teng (621662)

“…</p>Results<p>We observed 41 plant and 154 pollinator species, corresponding to 665 specific interactions. …”

Image2_Constructing more comprehensive pollination networks: integrating diurnal and nocturnal pollen data with visitation in a subalpine wetland community.jpeg by Yue Teng (621662)

“…</p>Results<p>We observed 41 plant and 154 pollinator species, corresponding to 665 specific interactions. …”

Data Sheet 1_Altered mitochondrial mass and low mitochondrial membrane potential of immune cells in patients with HBV infection and correlation with liver inflammation.pdf by Liling Ma (16752684)

“…In CHB patients with normal ALT but liver inflammation detected on B-scan ultrasonography, a significant decrease was observed in the MMP^low percentage of CD8⁺T (66.13 ± 14.27), CD56⁺NK(57.77 ± 17.40) and CD4^-CD8^-T (61.98 ± 15.98) cells. …”

<b>Contrasting strategies, shared risk: 12-yr nitrogen addition compromises hydraulic safety in young and mature trees via distinct pathways</b> by Shijie Ning (17757825)

“…We found that, in young trees, N50 decreased soluble sugars in leaves, twigs, and branches, but increased in roots, suggesting a preferential belowground allocation, whereas N20 responses were limited. …”

Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”